BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20170101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181112
DTEND;VALUE=DATE:20181114
DTSTAMP:20260515T013418
CREATED:20180620T145701Z
LAST-MODIFIED:20180620T145701Z
UID:16379-1541980800-1542153599@www.pharmajournalist.com
SUMMARY:Superbugs & Superdrugs USA
DESCRIPTION:Antimicrobial resistance\, leading to the development of superbugs\, is a major threat to public health and continues to increase as a problem\, due to continued misuse of antibiotics. With pharmaceutical companies showing less focus on the development of new antibiotics\, several incentive initiatives have been set up – CARBX\, BARDA\, IMI (EU) – in order to encourage reinvestments. \n\nTo address the ever-growing need of informative and thought-provoking discussions\, Superbugs & Superdrugs USA conference will offer a jam-packed agenda with presentations from key industry leaders and up-and-coming thinkers\, within the field. \nThis years’ Superbugs & Superdrugs USA conference programme will help participants to learn about pathogen focused drug development; discover the best methods to overcome bacterial resistance through novel modes of action; discuss the state of developments within the antifungal space; develop an understanding of funding opportunities which support antibacterial research and development; gain insight into new techniques through case-study examples of rapid diagnostic methods currently being used within the field\, making this event the perfect platform to strengthen knowledge in key principles. \nSpeakers include: \n\nAnthony Simon Lynch\, Senior Scientific Director\, Janssen\nWilliam Weiss\, Director\, Pre-Clinical Services\, UNT Health Science Center\nTina Guina\, Program Officer\, Drug Development Section\, NIAID/NIH\nMark Albrecht\, Project Officer\, HHS/ASPR/BARDA\nAntonio DiGiandomenico\, Principal Scientist\, MedImmune\nAndrew Tomaras\, VP & Director of Microbiology\, Bacterioscan\nDan Pevear\, Sr Vice President & Director of Microbiology\, VenatoRx\nIan Friedland\, Clinical Consultant\, ex-CMO\, Achaogen\n\nPlus\, topical workshops on November 14: \n\nRapid diagnostics for drug resistance: Are we there yet?\nAvoiding the post antibiotic era: the challenges and solutions to successful commercialisation of new antibiotics\n\nFurther details at http://www.superbugs-usa.com/PJWL \nTwitter – @SMIpharm & #smibugs\nLinkedIn – SMi Pharma
URL:https://www.pharmajournalist.com/event/superbugs-superdrugs-usa/
LOCATION:Renaissance Woodbridge Hotel\, 515 US Highway 1 South\, Iselin\, NJ\, United States
ORGANIZER;CN="SMi Group Ltd":MAILTO:ldurneva@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181112
DTEND;VALUE=DATE:20181116
DTSTAMP:20260515T013418
CREATED:20180926T135644Z
LAST-MODIFIED:20180927T081419Z
UID:17781-1541980800-1542326399@www.pharmajournalist.com
SUMMARY:World ADC San Diego
DESCRIPTION:9th Annual World ADC San Diego 2018 | 12-15 November\, 2018 | Marriott Marquis & Marina\, San Diego\, CA \nMaximizing the clinical therapeutic window of antibody-drug conjugates is a challenge we’re continuing the grapple with.  \nAs such\, there is a lot to be shared and discussed at this year’s 9th Annual World ADC San Diego. \n \nSince it’s conception in 2009 World ADC has risen to become the world’s leading and most comprehensive ADC meeting. The pinnacle event for thought-leading ADC drug developers.  \nOffering you an unparalleled learning and networking experience this year’s conference will share the very latest research advances\, enabling you to maximize the clinical therapeutic window of your ADC candidate. \nJoin over 650 drug developers across 220 organizations from the likes of Daiichi Sankyo\,Genentech\, Bristol Myers Squibb\, Immunomedics\, Immunogen\, Formation Biologics\, FDA and Sutro Biopharma to: \n\nHear unpublished data for the first time during the new Late Breaking Abstracts session\n\n\nAccess superior breadth of ADC research across 4 streams of parallel learning across discovery\, development\, clinical and manufacturing\n\n\nCommunicate your new results\, benchmark against your peers and gain invaluable feedback from the scientific community during the Poster Session\n\n\nGain tangible actions from discussing your challenges in one of the thirteen discussion led workshops\n\n\nRecognise your peer’s achievements and maybe yours?during the 5th Annual World ADC Awards ceremony\n\nFind out more https://info.hansonwade.com/worldadcsandiego \nDownload Full Agenda https://info.hansonwade.com/worldadcguide
URL:https://www.pharmajournalist.com/event/world-adc-san-diego/
LOCATION:Marriott Marquis San Diego\, 333 W Harbor Dr\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:adc@hansonwade.com
END:VEVENT
END:VCALENDAR